医师改良覆膜支架治疗复杂主动脉瘤的中期结局
本研究纳入日本10个主动脉中心2012年1月至2022年3月连续121例接受医师改良覆膜支架治疗的肾旁及胸腹主动脉瘤成人患者,评估早期与中期结局。结果显示院内死亡率为5.8%,胸腹主动脉瘤组术后IIIc型内漏发生率显著高于肾旁组(22.0% vs 8.1%,P=0.033),3年无全因死亡、无靶动脉瘤相关死亡及无再干预率两组均有显著差异。作者认为中期结局临床可接受,但肾旁与胸腹主动脉瘤为不同病理实体,术后结局不同。
要点
- 肾旁及胸腹主动脉瘤医师改良覆膜支架术后院内死亡率为5.8%。
- 胸腹主动脉瘤组IIIc型内漏发生率显著高于肾旁组(22.0% vs 8.1%,P=0.033)。
- 3年无全因死亡率肾旁组83.3% vs 胸腹组54.1%(P=0.004)。
核心结论
- 医师改良覆膜支架治疗肾旁及胸腹主动脉瘤的中期结局临床可接受,与其他近期发表研究相当。
- 肾旁与胸腹主动脉瘤为不同病理实体,术后结局不同。
研究设计与样本
- 多中心回顾性队列研究,纳入日本10个主动脉中心2012年1月至2022年3月连续121例接受医师改良覆膜支架治疗的肾旁及胸腹主动脉瘤成人患者。
主要发现
- 肾旁组62例(51.2%),胸腹组59例(48.8%)。
- 总体院内死亡率为5.8%(n=7),肾旁组3.2%(n=2) vs 胸腹组8.5%(n=5),P=0.225。
- 术后IIIc型内漏18例(14.9%),胸腹组22.0%(n=13) vs 肾旁组8.1%(n=5),P=0.033。
- 主要不良事件肾旁组7例(11.3%) vs 胸腹组14例(23.7%),P=0.074。
- 平均随访24.2个月,3年时肾旁组 vs 胸腹组:无全因死亡率83.3% vs 54.1%(P=0.004);无靶动脉瘤相关死亡率96.8% vs 82.7%(P=0.013);无再干预率89.3% vs 65.6%(P=0.002)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Our goal was to evaluate early and mid-term outcomes of physician-modified endografting for pararenal and thoraco-abdominal aortic aneurysms from 10 Japanese aortic centres. METHODS: From January 2012 to March 2022, a total of 121 consecutive adult patients who underwent physician-modified endografting for pararenal and thoraco-abdominal aortic aneurysms were enrolled. We analysed early and mid-term postoperative outcomes, including postoperative complications and mortality. RESULTS: The pararenal and thoraco-abdominal aortic aneurysm groups included 62 (51.2%) and 59 (48.8%) patients, respectively. The overall in-hospital mortality rate was 5.8% (n = 7), with mortality rates of 3.2% (n = 2) and 8.5% (n = 5) in pararenal and thoraco-abdominal aortic aneurysm groups, respectively (P = 0.225). Type IIIc endoleaks occurred postoperatively in 18 patients (14.9%), with a significantly higher incidence (P = 0.033) in the thoraco-abdominal aortic aneurysm group (22.0%, n = 13) than in the other group (8.1%, n = 5). Major adverse events occurred in 7 (11.3%) and 14 (23.7%) patients in pararenal and thoraco-abdominal aortic aneurysm groups (P = 0.074), respectively. The mean follow-up period was 24.2 months. At the 3-year mark, both groups differed significantly in freedom from all-cause mortality (83.3% and 54.1%, P = 0.004), target aneurysm-related mortality (96.8% and 82.7%, P = 0.013) and any reintervention (89.3% and 65.6%, P = 0.002). Univariate and multivariate regression analyses demonstrated that ruptures, thoraco-abdominal aortic aneurysms and postoperative type IIIc endoleaks were associated with an increased risk of all-cause mortality. CONCLUSIONS: The mid-term outcomes of physician-modified endografting for pararenal and thoraco-abdominal aortic aneurysms were clinically acceptable and comparable with those in other recently published studies. Notably, pararenal and thoraco-abdominal aortic aneurysms represent distinct pathological entities with different postoperative outcomes.
引用
- Shibata T, Mitsuoka H, Iba Y, et al. Mid-term outcomes of physician-modified endograft therapy for complex aortic aneurysms. Interdiscip Cardiovasc Thorac Surg. 2024. PMID: 38490250. doi:10.1093/icvts/ivae044
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。